Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in β-Thalassemia

Patrick B. Walter, PhD, Nick Slater, BS, Paul Harmatz, MD, Annie Higa, BS, Vivian Ng, BS, Marcels Weyhmiller, Patricia Evans, PhD, John B Porter, Nancy Sweeters, Jackson Price, BS, David Killilea, PhD, Lynne Neumayr, MD, Ashutosh Lal, MD, Elliott Vichinsky, MD

Blood (2015) 126 (23): 950.

https://doi.org/10.1182/blood.V126.23.950.950

Published: 2015

Journal Articles

Determinants Of Tissue Iron Loading In Transfused and Non-Transfused β-Thalassemia and Sickle Cell Disease Patients – Biomarkers Of Iron Regulation and Inflammation

Patrick B Walter, PhD, Zahra Pakbaz, MD, Elizabeta Nemeth, PhD, Tomas Ganz, MD, PhD, John B Porter, MD, Patricia Evans, PhD, Kelsey M Houston, Roland Fischer, PhD, Marcela G Weyhmiller, PhD, Matt Herz, Bs, Jeffery L Miller, MD, Robert Hagar, MD, Lynne D Neumayr, MD, Elliott Vichinsky, MD, Paul Harmatz, MD

Blood (2013) 122 (21): 1017.

https://doi.org/10.1182/blood.V122.21.1017.1017

Published: 2013

Journal Articles

Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study)

John Porter, MD, Patrick B Walter, PhD, Lynne D Neumayr, MD, Patricia Evans, PhD, Marcela G Weyhmiller, PhD, Paul Harmatz, MD, John C. Wood, MD, PhD, Jeffery L Miller, MD, Guenter Weiss, MD, Quing Yuan, PhD, Zhiyue J Wang, PhD, Regine Grosse, MD, Bjoern P Schoennagel, MD, Joerg Meerpohl, MD, Roland Fischer, PhD, Peter Nielsen, MD, Markus Seifert, BSc, Elliott Vichinsky, MD

Blood (2013) 122 (21): 1014.

https://doi.org/10.1182/blood.V122.21.1014.1014

Published: 2013

Journal Articles

Innate Immune Cell Expression of Pattern Recognition Receptors From β-Thalassemia Patients During Intensive Combination Chelation Therapy

Patrick B Walter, PhD, Paul Harmatz, MD, Annie Higa, B.S., Vivian Ng, B.S., Marcela G Weyhmiller, PhD, Patricia Evans, PhD, John B. Porter, MD, Nancy Sweeters, RN, PNP, Jackson Price, B.S., Alisha Manji, B.S., David Killilea, PhD, Ashutosh Lal, MD, Elliott Vichinsky, MD

Blood (2012) 120 (21): 1025.

https://doi.org/10.1182/blood.V120.21.1025.1025

Published: 2012

Journal Articles

Iron Trafficking and Distribution in Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia with Sickle Cell Disease and Thalassemia

John B. Porter, MD, Patrick B Walter, PhD, Lynne D Neumayr, MD, Patricia Evans, PhD, Marcela G Weyhmiller, PhD, Paul Harmatz, MD, John C Wood, MD, Ph.D, Jeffery L. Miller, Guenter Weiss, MD, Qing Yuan, Zhiyue J Wang, Regine Grosse, MD, Bjoern P Schoennagel, Joerg Meerpohl, Roland Fischer, PhD, Elliott Vichinsky, MD

Blood (2012) 120 (21): 995.

https://doi.org/10.1182/blood.V120.21.995.995

Published: 2012

Journal Articles

A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload

Ellis J. Neufeld, Renzo Galanello, Vip Viprakasit, Yesim Aydinok, Antonio Piga, Paul Harmatz, Gian Luca Forni, Farrukh T. Shah, Rachael F. Grace, John B. Porter, John C. Wood, Jennifer Peppe, Amber Jones, Hugh Young Rienhoff, Jr

Blood (2012) 119 (14): 3263–3268.

https://doi.org/10.1182/blood-2011-10-386268

Published: 2012

Includes: Supplemental data

Journal Articles

Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study

Ellis J. Neufeld, MD, PhD, Renzo Galanello, MD, Vip Viprakasit, MD; DPhil, Yesim Aydinok, MD, Antonio Piga, MD, Paul Harmatz, MD, Gian Luca Forni, MD, Farrukh T Shah, MBBS, MD, Rachael F. Grace, MD, John B. Porter, MD, Elliott Vichinsky, MD, John C Wood, MD, Ph.D, Jennifer Peppe, Amber Jones, Hugh Y Rienhoff, Jr., MD

Blood (2011) 118 (21): 690.

https://doi.org/10.1182/blood.V118.21.690.690

Published: 2011

Journal Articles

A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload

Hugh Y. Rienhoff, Jr, MD, ip Viprakasit, MD, D, Phil, Lay H. Tay, MBBS, FRCPA, Paul Harmatz, MD, Elliott Vichinsky, MD, Deborah Chirnomas, MD, MPH, Janet Kwiatkowski, MD, Amy E Tapper, PhD, John B Porter, MD, Ellis J. Neufeld, MD, PhD

Blood (2010) 116 (21): 2057.

https://doi.org/10.1182/blood.V116.21.2057.2057

Published: 2010

Journal Articles

Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia

Ashutosh Lal, MD, Nancy Sweeters, PNP, Vivian Ng, Drucilla Foote, PNP, Patricia Evans, PhD, Lynne Neumayr, MD, Gregory Kurio, MD, Paul Harmatz, MD, John B. Porter, MD, Elliott Vichinsky, MD

Blood (2010) 116 (21): 4269.

https://doi.org/10.1182/blood.V116.21.4269.4269

Published: 2010

Journal Articles

Pulmonary Hypertension Is Uncommon In Well-Transfused Thalassemia Major Patients

Jon Detterich, MD, Leila Noetzli, BS, Susan Carson, PNP, Paul Harmatz, MD, Thomas D. Coates, MD, John C Wood, MD, PhD

Blood (2010) 116 (21): 4273.

https://doi.org/10.1182/blood.V116.21.4273.4273

Published: 2010

Journal Articles

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel

Blood (2010) 116 (16): 2875–2883.

https://doi.org/10.1182/blood-2009-11-248724

Published: 2010

Journal Articles

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

John C. Wood, Barinder P. Kang, Alexis Thompson, Patricia Giardina, Paul Harmatz, Tara Glynos, Carole Paley, Thomas D. Coates

Blood (2010) 116 (4): 537–543.

https://doi.org/10.1182/blood-2009-11-250308

Published: 2010

Journal Articles

Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.

Patrick B Walter, PhD, John B Porter, MD, Patricia Evans, PhD, Janet Kwiatkowski, MD, Ellis J. Neufeld, MD, PhD, Thomas D. Coates, MD, Patricia Giardina, MD, Robert jW Grady, PhD, Elliott Vichinsky, MD, Nancy F. Olivieri, MD, Felicia Trachtenberg, PhD, Daniele Alberti, MD, Ellen Fung, PhD, Bruce Ames, PhD, Annie Lui, BS, Paul Harmatz, MD

Blood (2008) 112 (11): 1868.

https://doi.org/10.1182/blood.V112.11.1868.1868

Published: 2008

Journal Articles

Deferasirox (Exjade ® ) Monotherapy Significantly Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study

John C Wood, Alexis A. Thompson, MD, MPH, Carole Paley, Barinder Kang, Patricia Giardina, Paul Harmatz, M.D., Jodi Virkus, Thomas D Coates

Blood (2008) 112 (11): 3882.

https://doi.org/10.1182/blood.V112.11.3882.3882

Published: 2008

Journal Articles

Prolonged QTc in Sickle Cell Disease: A Potential Risk Factor for Early Death?

Sean Lindstedt, Lynne Neumayr, M.D., Gregory Kurio, M.D., Claudia Morris, M.D., Shanda Robertson, Ellen Fung, PhD, Paul Harmatz, M.D., John C Wood, MD, PhD, Elliott P. Vichinsky, M.D.

Blood (2008) 112 (11): 2476.

https://doi.org/10.1182/blood.V112.11.2476.2476

Published: 2008

Journal Articles

Liver Iron Measurement by SQUID Biosusceptometry Compared to Liver Biopsy: A More Accurate Definition of Optimal Iron Range.

Zahra Pakbaz, MD, Roland Fischer, PhD, Elliott Vichinsky, MD, Robert L. Fagaly, PhD, Douglas Paulson, PhD, Kevin Pratt, John Butz 5, Drucilla Foote, PNP, Keith Quirolo, MD, Paul Harmatz, MD

Blood (2007) 110 (11): 2675.

https://doi.org/10.1182/blood.V110.11.2675.2675

Published: 2007

Journal Articles

Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine.

Patrick B. Walter, PhD, John Porter, MD, Patricia Evans, PhD, Janet L. Kwiatkowski, MD, Ellis J. Neufeld, MD, Thomas Coates, MD, Patricia J. Giardina, MD, Robert W. Grady, PhD, Elliott Vichinsky, MD, Nancy F. Olivieri, MD, Felicia Trachtenberg, PhD, Daniele Alberti, MD, Jaymes Holland, PhD, Ellen Fung, PhD, Bruce Ames, PhD, Annie Lui, BS, Paul Harmatz, MD

Blood (2007) 110 (11): 2773.

https://doi.org/10.1182/blood.V110.11.2773.2773

Published: 2007

Journal Articles

Safety and Efficacy of Peginterferon Alfa-2a and Ribavirin for Hepatitis C in Thalassemia.

Paul Harmatz, MD, Nancy F. Olivieri, MD, Janet Kwiatkowski, MD, Elliott Vichinsky, MD, Patricia Giardina, MD, Farrukh Shah, MD, Elizabeth C. Wright, PhD, Roland Fischer, PhD, Maureen M. Jonas, MD

Blood (2006) 108 (11): 558.

https://doi.org/10.1182/blood.V108.11.558.558

Published: 2006

Journal Articles

Iron Overload in Acute Myelogenous Leukemia after Bone Marrow Transplantation.

Zahra Pakbaz, MD, Roland Fischer, PhD, Nancy Noonan, RN, Sherrie Shiota, PA, Paul Harmatz, MD, Elliott Vichinsky, MD, Mark C. Walters, MD

Blood (2006) 108 (11): 5336.

https://doi.org/10.1182/blood.V108.11.5336.5336

Published: 2006

Journal Articles

Fracture Prevalence and Relationship to Endocrinopathy in Iron Overloaded Patients with Sickle Cell Disease and Thalassemia.

Ellen B. Fung, PhD, RD, Paul Harmatz, MD, Meredith Milet, MS, Elliott Vichinsky, MD

Blood (2006) 108 (11): 459.

https://doi.org/10.1182/blood.V108.11.459.459

Published: 2006

NARROW

Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in β-Thalassemia

Determinants Of Tissue Iron Loading In Transfused and Non-Transfused β-Thalassemia and Sickle Cell Disease Patients – Biomarkers Of Iron Regulation and Inflammation

Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study)

Innate Immune Cell Expression of Pattern Recognition Receptors From β-Thalassemia Patients During Intensive Combination Chelation Therapy

Iron Trafficking and Distribution in Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia with Sickle Cell Disease and Thalassemia

A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload

Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study

A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload

Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia

Pulmonary Hypertension Is Uncommon In Well-Transfused Thalassemia Major Patients

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.

Deferasirox (Exjade ® ) Monotherapy Significantly Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study

Prolonged QTc in Sickle Cell Disease: A Potential Risk Factor for Early Death?

Liver Iron Measurement by SQUID Biosusceptometry Compared to Liver Biopsy: A More Accurate Definition of Optimal Iron Range.

Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine.

Safety and Efficacy of Peginterferon Alfa-2a and Ribavirin for Hepatitis C in Thalassemia.

Iron Overload in Acute Myelogenous Leukemia after Bone Marrow Transplantation.

Fracture Prevalence and Relationship to Endocrinopathy in Iron Overloaded Patients with Sickle Cell Disease and Thalassemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only